Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Combinatorial chemistry involves simultaneously synthesizing a large number of related compounds for high-throughput analysis. Chemical biologists are able to use principles from combinatorial chemistry in synthesizing active drug compounds and maximizing screening efficiency. Similarly, these principles can be used in areas of agriculture and food research, specifically in the syntheses of unnatural products and in generating novel enzyme inhibitors.
Additionally, the research, in conjunction with studies that show tyrannosaurs were more agile than other large-bodied theropods, indicates they were quite well-adapted to a long-distance stalking approach followed by a quick burst of speed to go for the kill. Analogies can be noted between tyrannosaurids and modern wolves as a result, supported by evidence that at least some tyrannosaurids were hunting in group settings. A study published in 2021 by Pasha van Bijlert et al., calculated the preferred walking speed of Tyrannosaurus, reporting a speed of 1.28 meters per second (4.6 km/h; 2.9 mph). While walking, animals reduce their energy expenditure by choosing certain step rhythms at which their body parts resonate. The same would have been true for dinosaurs, but previous studies did not fully account for the impact the tail had on their walking speeds. According to the authors, when a dinosaur walked, its tail would slightly sway up and down with each step as a result of the interspinous ligaments suspending the tail. Like rubber bands, these ligaments stored energy when they are stretched due to the swaying of the tail. Using a 3-D model of Tyrannosaurus specimen Trix, muscles and ligaments were reconstructed to simulate the tail movements. This results in a rhythmic, energy-efficient walking speed for Tyrannosaurus similar to that seen in living animals such as humans, ostriches and giraffes.
==== Monoclonal antibodies ==== Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis). Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones. It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone. While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx. In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.
=== Initial production === Plutonium-238 was the first isotope of plutonium to be discovered. It was synthesized by Glenn Seaborg and his associates in December 1940 by bombarding uranium-238 with deuterons, creating neptunium-238. 23892U + 21H → 23893Np + 2n The neptunium isotope then undergoes β− decay to plutonium-238 with a half-life of 2.099 days. Plutonium-238 naturally decays to uranium-234 and then continues, after a long period of time, along the radium series to lead-206. Historically, most plutonium-238 has been produced by Savannah River in their weapons reactor, by irradiating neptunium-237 (half life 2.144 Ma) with neutrons. 23793Np + n → 23893Np Neptunium-237 is a by-product of the production of plutonium-239 weapons-grade material, and when the site was shut down in 1988, 238Pu was mixed with about 16% 239Pu.
The Houthi movement in Yemen warned that it would respond to any escalation against Iran, including efforts to reopen the Strait of Hormuz. It specifically warned the two Arab countries offering to join the Strait of Hormuz campaign—Bahrain and the UAE—that they "will be the first to lose in this battle". The Houthis further threatened to join the war in the event that US allies joined the attack on Iran or if the US and Israel used the Red Sea to carry out operations. Lebanon's government expelled the Iranian ambassador. Trump issued an ultimatum to Iran, threatening to strike its power plants unless it opened the strait within 48 hours. Iran doubled down, threatening to "completely" close the strait and strike vital infrastructure across the region such as energy and desalination facilities critical for drinking water. Iranian opposition figure and former crown prince Reza Pahlavi called on Trump and Netanyahu to target the military while sparing civilian infrastructure which "Iranians will need to rebuild our country." Halfway through the deadline, Trump announced that he was postponing strikes against Iranian power plants for five days, and said the US was negotiating with Iran to end the war. Iran denied the talks ever took place or were taking place, calling him "deceitful". Iran rejected the 15-point peace plan presented by the US. Iran asserted that Lebanon must be included as part of a ceasefire deal, thereby making a ceasefire conditional on an end to the 2026 Lebanon war against Hezbollah.
Sources: en.wikipedia.org
=== 2018 presidential election === In 2017, Peña ran for the Colorado Party's presidential candidacy in the 2018 general election, ultimately losing out to Mario Abdo Benítez, with Abdo Benítez winning 564,811 votes (50.93%) to Peña's 480,114 (43.29%). Following his defeat in the Colorado Party's internal elections in 2017, Peña was elected to the board of Banco Amambay in March 2018. The bank was part of the Cartes Group, which was owned by former President of Paraguay Horacio Cartes, for whom Peña had served as minister of finance.
== Botany == In botany, the term is most common in its adjectival forms, where it is used in binomial names to refer to species that are distinguished by hollow or tubular structures. Monarda fistulosa, for example, has tubular flowers; Eutrochium fistulosum has a tubular stem; Allium fistulosum has hollow or tubular leaves, and Acacia seyal subsp. fistula is the subspecies with hollow spines.
are the respective mole fractions and viscosities of the component liquids. Since blending is an important process in the lubricating and oil industries, a variety of empirical and proprietary equations exist for predicting the viscosity of a blend.
Robbins (1963), psychiatrist, scholar on expatriate communities in India Richard Waldinger (1963), computer scientist, fellow of the Association for the Advancement of Artificial Intelligence Allan Blaer (1964), physicist and professor who is in charge of the Columbia University Science Honors Program Frederick Kantor (1964), physicist, inventor of glancing incidence X-ray telescope Richard A. Muller (1964), professor of physics at the University of California, Berkeley; winner of the MacArthur Fellowship in 1982 and the Alan T. Waterman Award in 1978; founder of climate science institute Berkeley Earth Kenneth Prager (1964), physician, professor at Columbia University Medical Center, brother of commentator Dennis Prager Mark C. Rogers (1964), physician, former CEO of Duke University Health System Michael Terman (1964), Columbia University Medical Center psychologist Norman Christ (1965), physicist, professor at Columbia University Niles Eldredge (1965), collaborator of Stephen Jay Gould and curator of the Department of Invertebrates at the American Museum of Natural History Alan I. Green (1965), professor at Geisel School of Medicine, nephew of Herman Wouk Stuart Newman (1965), developmental and evolutionary biologist Allen Steere (1965), rheumatologist and pioneering investigator of Lyme disease Sylvain Cappell (1966), mathematician, professor at the Courant Institute of Mathematical Sciences Barry S.
Maggot therapy has been shown to accelerate debridement of necrotic wounds and reduce the bacterial load of the wound, leading to earlier healing, reduced wound odor and less pain. The combination and interactions of these actions make maggots an extremely potent tool in chronic wound care. Negative pressure wound therapy (NPWT) is a treatment that improves ischemic tissues and removes wound fluid used by bacteria. This therapy, also known as vacuum-assisted closure, reduces swelling in tissues, which brings more blood and nutrients to the area, as does the negative pressure itself. The treatment also decompresses tissues and alters the shape of cells, causes them to express different mRNAs and to proliferate and produce ECM molecules. Recent technological advancements produced novel approaches such as self-adaptive wound dressings that rely on properties of smart polymers sensitive to changes in humidity levels. The dressing delivers absorption or hydration as needed over each independent wound area and aids in the natural process of autolytic debridement. It effectively removes liquefied slough and necrotic tissue, disintegrated bacterial biofilm as well as harmful exudate components, known to slow the healing process. The treatment also reduces bacterial load by effective evacuation and immobilization of microorganisms from the wound bed, and subsequent chemical binding of available water that is necessary for their replication.
Sources: en.wikipedia.org
== Cannabinoid receptors == Cannabinoid receptor 1 (CBR1) and Cannabinoid receptor 2 (CBR2) are the two main binding targets in the endocannabinoid system. They share similar molecular shape and signalling mechanisms, but differ in their tissue distribution and effects. CB1R mainly presents in the central nervous system, with its activation commonly associated with the regulation of mood, pain and appetite. CB2R is abundant in the immune tissues, for example spleen, lymph nodes and bone marrow. Its activation causes immunosuppressive effects.
== Method of action == Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.
== Behavior and diet == It is a secretive species and is seldom encountered by humans. It is active by day and night, though it is usually more active by day. This largely aquatic snake spends most of its time in the water. It is an excellent swimmer and is capable of remaining underwater for up to 10 minutes and diving to depths of 25 m (82 ft). It is a slow mover on land, and it tends to hide among rocks, in holes, or overhanging tree roots at the shoreline. It also makes use of any man-made structures, such as bridges and jetties, to hide. It is generally not aggressive, and if approached in water, it will swim away swiftly and on land will attempt to escape into water. If threatened on land, it will rear up and spread its narrow, yet prominent hood and it may hiss loudly, but it tends not to make any forward movements. It will only bite when provoked. It preys almost exclusively on fish. It may also prey on frogs, toads, and other amphibians.
=== Tolerance dose === In 1931, the U.S. Advisory Committee on X-Ray and Radium Protection (ACXRP, now the National Council on Radiation Protection and Measurements, NCRP), founded in 1929, published the results of a study on the so-called tolerance dose, on which a scientifically based radiation protection guideline was based. Exposure limits were gradually lowered. In 1936 the tolerance dose was 0.1 R/day. The unit "R" (the X-ray) from the CGS unit system has been obsolete since the end of 1985. Since then, the SI unit of ion dose has been "coulomb per kilogram".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.